Biotech Values

[walldiver]

It's stunning, I agree. A lot of focus is on the median PFS, which is statistically significant but not clinically significant. However, once you get toward the PFS at the 65 and 75 percentiles, satra was quite significant clinically. On the other hand, the FDA is clearly not happy that GPCB has been claiming the whole time that GPCB met its obligations concerning the signed SPA. Including the pain metric in the PFS endpoint, plus using the PFS endpoint in the first place, was a no-no.